Fast Track: Editor's choice: HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver … Richard Haynes , Lixin Jiang , Jemma C Hopewell , Jing Li , Fang Chen , Sarah Parish , Martin J Landray , Rory Collins , Jane Armitage , R Collins , J Armitage , C Baigent , Z Chen , M Landray , Y Chen , L Jiang , T Pedersen , M Landray , L Bowman , F Chen , M Hill , R Haynes , C Knott , K Rahimi , J Tobert , P Sleight , D Simpson , S Parish , A Baxter , M Lay , C Bray , E Wincott , G Leijenhorst , A Skattebol , G Moen , Y Mitchel , O Kuznetsova , S MacMahon , J Kjekshus , C Hill , TH Lam , P Sandercock , R Peto , JC Hopewell , HPS-THRIVE Collaborative Group European Heart Journal（2013）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
